Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta) (STORE)

23. april 2018 oppdatert av: Janssen-Cilag S.p.A.

Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta®): the STart Of REzolsta (ST.O.RE.) Study

The purpose of this study is to describe the effectiveness of darunavir/cobicistat (DRV/c)-based regimens, measured as maintenance of virological suppression 48 weeks after baseline, defined as the day when the treatment with DRV/c-based regimen is started, through collection of daily practice data in the Italian setting.

Studieoversikt

Status

Fullført

Forhold

Studietype

Observasjonsmessig

Registrering (Faktiske)

337

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adult out-patients with a confirmed diagnosis of Human Immunodeficiency Virus-1 (HIV-1), belonging to Italian Infectious Disease Hospital departments of Italian specialty hospitals.

Beskrivelse

Inclusion Criteria:

  • Adult greater than or equal to (>=18 years), male and female patients
  • Documented Human Immunodeficiency Virus-1 (HIV-1) infection
  • Eligible to darunavir/cobicistat (DRV/c) treatment according to Summary of Product Characteristics
  • Patients who are able to understand the nature of the study and to provide their consent voluntarily having signed an Informed Consent Form (ICF) allowing data collection and source data verification in accordance with local requirements
  • Patients in stable (>= 12 months) treatment with an Antiretroviral (ARV) therapy PI/ritonavir (PI/r)-based, being prescribed Rezolsta (DRV/c) by treating physician
  • Patients virosuppressed (HIV-RNA less than [<] 50 copies/milliliters) since at least 6 months, within their HIV treatment at the moment of enrollment; single values of HIV-RNA more than [>] 50 copies/ml not confirmed (blips) will be considered acceptable; last value collected being < 50 copies/ml

Exclusion Criteria:

  • Patient currently enrolled in an interventional study
  • Patient currently enrolled in an observational study sponsored or supported by Janssen
  • Estimated Glomerular Filtration Rate (eGFR) < 70 milliliters per minute (ml/min) if any co-administered agent (example emtricitabine, lamivudine, tenofovir disoproxil fumarate, or adefovir dipivoxil) requires dose adjustment based on creatinine clearance
  • Pregnancy or breast feeding at enrollment
  • Allergy or intolerance to sulphonamides
  • Switch from darunavir/ritonavir (DRV/r) 600/100 bis in die (bid)
  • Patient currently in mono PI/r therapy
  • Patients to be treated within one year with Direct Acting Antivirals (DAAs) for Hepatitis C Virus (HCV) infection
  • Chemotherapy scheduled

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Cohort 1
HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram [mg] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than [<]50 copies/milliliters) since at least six months.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Patients With Human Immunodeficiency Virus - RiboNucleic Acid (HIV-RNA) Less Than (<)50 Copies/Milliliters (copies/mL) Measured at Week 48
Tidsramme: At Visit 4 (Week 48)
The percentage of patients with plasma HIV-RNA<50 copies/mL will be analyzed by FDA snapshot analysis (FDA Snapshot Approach is based on the last observed viral load data within the Week 48 window: virologic response is defined as HIV-1 RNA <50 copies/mL (observed case); If there are no data in the defined time window, the proportion of missing data and relative reason will be provided") and Time to loss of virologic response (TLOVR) method algorithm requires sustained HIV-1 RNA < 50 copies/mL; confirmed HIV-1 RNA more than or equal to (>=) 50 copies/mL is considered as non-response (rebound); patients considered non-responder after permanent discontinuation).
At Visit 4 (Week 48)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in HIV-Symptoms Distress Module (HIV-SDM) Score
Tidsramme: Baseline, Up to Visit 4 (Week 48)
HIV-SDM is a questionnaire consisting of 20 questions related to all the symptoms which the patient might have had during the past four weeks. For each question patient has to select appropriate answer related to the symptoms: "0 = I do not have this symptom; 1 = I have this symptom and it doesn't bother me; 2 = it bothers me a little; 3 = it bothers me; 4 = it bothers me a lot".
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in HIV-Treatment Satisfaction Questionnaire (HIV-TSQ) Score
Tidsramme: Baseline, Up to Visit 4 (Week 48)
The HIV Treatment Satisfaction Questionnaire (HIV-TSQ) is a 10-item instrument that is supported by evidence of good internal consistency reliability. The total score ranges from 0 to 60, with higher scores indicating greater treatment satisfaction. Score change ranges from -30 to +30, with scores<0 and >0 indicating a decrease and increase in treatment satisfaction, respectively.
Baseline, Up to Visit 4 (Week 48)
Percentage of Patients with HIV-RNA <50 copies/mL Measured at Week 24
Tidsramme: At Visit 3 (Week 24)
At Visit 3 (Week 24)
Change From Baseline in CD4 Cell Count
Tidsramme: Baseline, Up to Visit 4 (Week 48)
CD4 cell count will be assessed as immunological parameter.
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in CD4/CD8 Ratio
Tidsramme: Baseline, Up to Visit 4 (Week 48)
CD4/CD8 ratio will be assessed as immunological parameter.
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in CD4 Percentage
Tidsramme: Baseline, Up to Visit 4 (Week 48)
CD4 percentage will be assessed as immunological parameter.
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Creatinine Levels
Tidsramme: Baseline, Up to Visit 4 (Week 48)
The change from baseline in serum creatinine up to 48 weeks will be assessed.
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in estimated Glomerular Filtration Rate (eGFR)
Tidsramme: Baseline, Up to Visit 4 (Week 48)
The change from baseline in eGFR will be assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Aspartate Transferase (AST)
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Alanine-Amino Transferase (ALT)
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Gamma-Glutamyl Transferase (GGT)
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Alkaline Phosphatase (ALP)
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Total Cholesterol
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Low Density Lypoprotein (LDL)
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in High Density Lypoprotein (HDL)
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Triglycerides
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)
Change From Baseline in Glucose
Tidsramme: Baseline, Up to Visit 4 (Week 48)
Baseline, Up to Visit 4 (Week 48)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Janssen-Cilag S.p.A.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. juli 2016

Primær fullføring (Faktiske)

14. februar 2018

Studiet fullført (Faktiske)

14. februar 2018

Datoer for studieregistrering

Først innsendt

21. september 2016

Først innsendt som oppfylte QC-kriteriene

5. oktober 2016

Først lagt ut (Anslag)

6. oktober 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. april 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. april 2018

Sist bekreftet

1. april 2018

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • CR108148
  • TMC114FD1HTX4003 (Annen identifikator: Janssen-Cilag S.p.A., Italy)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Humant immunsviktvirus

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Kyrgyzstan

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

3
Abonnere